| Name | Role | Date | Shares | Price | Value | 
|---|---|---|---|---|---|
| Gabriel Brooks | Chief Medical Officer | 2025-10-20 | 2,895 | $5.96 | $17.25kSell | 
| Clare Kahn | Director | 2025-03-11 | 1,860 | $5.34 | $9.92kBuy | 
| Bain Capital Life Sciences Investors LLC | 10% Owner | 2025-02-19 | 1,000,000 | $4.03 | $4.03MBuy | 
| Perceptive Advisors LLC | Director | 2025-02-19 | 5,000,000 | $4.03 | $20.15MBuy | 
| Adage Capital Management LP | 10% Owner | 2025-02-18 | 252,545 | $7.56 | $1.91MBuy | 
| Kevin Tan | CFO Treasurer | 2025-02-14 | 3,164 | $3.96 | $12.53kSell | 
| Gabriel Brooks | Chief Medical Officer | 2025-02-14 | 3,256 | $3.96 | $12.89kSell | 
| Alexander Cumbo | President and CEO | 2025-02-14 | 11,365 | $3.96 | $45.01kSell | 
| Ilan Ganot | Director | 2025-02-14 | 1,711 | $3.96 | $6.78kSell | 
| Jessie Hanrahan | Chief Regulatory Officer | 2025-02-14 | 3,079 | $3.96 | $12.19kSell | 
| Name | Hold | Shares | Value | Type | 
|---|---|---|---|---|
| Rajeev M. Shah | 17.06% | 13,281,046 | $78.62M | Insider | 
| Perceptive Advisors LLC | 15.29% | 11,906,646 | $70.49M | Institution | 
| Ra Capital Management LP | 15.01% | 11,689,948 | $69.20M | Insider | 
| Bain Capital Life Sciences Investors LLC | 10.16% | 7,911,669 | $46.84M | Institution | 
| Ultragenyx Pharmaceutical Inc | 10.05% | 7,825,797 | $46.33M | Insider | 
| Siren LLC | 9.52% | 7,415,905 | $43.90M | Institution | 
| Adage Capital Partners GP LLC | 8.64% | 6,729,484 | $39.84M | Institution | 
| Ra Capital Management LP | 7.46% | 5,811,323 | $34.40M | Institution | 
| Gilad David Hayeem | 6.60% | 5,136,501 | $30.41M | Insider | 
| Bain Capital Life Sciences Investors LLC | 6.47% | 5,034,582 | $29.80M | Insider |